References
- Comarmond C, Mirault T, Biard L, Nizard J, Lambert M, Wechsler B, et al. Takayasu arteritis and pregnancy. Arthritis Rheumatol 2015;67:3262–9.
- Hoeltzenbein M, Beck E, Rajwanshi R, Skorpen CG, Berber E, Schaefer C, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 2016;46:238–45.
- Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol 2016;26:667–71.
- Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy – a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol 2016;60:29–32.
- Saito J, Yakuwa N, Takai C, Nakajima K, Kaneko K, Goto M, et al. Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study. Rheumatology (Oxford) 2018;57:1499–501.
- Saito J, Yakuwa N, Kaneko K, Takai C, Goto M, Nakajima K, et al. Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum. Rheumatology (Oxford). Published online 3 March 2019. doi:10.1093/rheumatology/kez100.
- Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumour necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286–92.